GlassScriptPhysician profile
Ryan L Allen
NPI 1265417752
$12,527.66
in general payments reported to CMS, 2019-2025
41 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,641 · 2020: $2,025 · 2021: $2,691 · 2022: $1,958 · 2023: $1,459 · 2024: $1,528 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,214.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,794.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,345.75 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $1,102.36 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,098.13 | 2019-2025 | |
| Lilly USA, LLC | $949.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $913.28 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $810.56 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $544.86 | 2021-2024 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $498.47 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $413.34 | 2020-2025 | Trintellix |
| Mylan Specialty L.P. | $410.41 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $408.62 | 2022-2025 | |
| Exact Sciences Corporation | $257.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $245.46 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $228.97 | 2020-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.